| Excerpt | Reference |
|---|
| "A right atrial thrombus is not often seen and only a few reports of visualization have been described." | ( Hayashi, M; Hayashida, K; Misawa, T; Nishimura, T; Park, YD; Uehara, T, 1987) |
| "The thrombus is squeezed by the vascular constriction and thus mechanically held in place and squeezed out." | ( Herrmann, KS; Kreuzer, H, 1988) |
| "When the thrombus is not well visualised, it is necessary to complete the investigation with bilateral phlebocavography in free flow or with a computerised tomography scan if the vena cava is poorly seen." | ( Bonnet, JL, 1995) |
| "If no thrombus is seen, cardioversion is then performed." | ( Manning, WJ; Seto, TB; Taira, DA; Tsevat, J, 1997) |
| "Intrahepatic thrombus is usually associated with either cirrhosis or hepatocellular carcinoma (HCC)." | ( Anglade, MC; Coffin, C; Lonjedo, E; Marti-Bonmati, L; Mathieu, D; Poyatos, C, 1997) |
| "Thrombus is believed to be deleterious to intimal function." | ( Gelabert, HA; Henderson, TC; Moore, WS; Nene, S; Quiñones-Baldrich, WJ, 1999) |
| "We conclude that thrombus is deleterious to endothelial function independent of smooth muscle function in the acute setting as measured by endothelial-dependent vasorelaxation." | ( Gelabert, HA; Henderson, TC; Moore, WS; Nene, S; Quiñones-Baldrich, WJ, 1999) |
| "Because blood clots are porous objects exposed to local hemodynamic forces, pressure-driven interstitial permeation often controls drug penetration and the overall lysis rate of an occlusive thrombus." | ( Diamond, SL, 1999) |
| "The liquefied thrombus is then aspirated." | ( Diethrich, EB; Kasirajan, K; Ramaiah, VG, 2003) |
| "When a blood clot is formed, vitronectin (VN) is incorporated." | ( Bloemendal, HJ; de Boer, HC; de Groot, PG; Gebbink, MF; Logtenberg, T; Voest, EE; Wu, YP, 2004) |
| "The growing thrombus is assumed to be porous and having low permeability, that is in good agreement with experimental data." | ( Lobanov, AI; Starozhilova, TK, 2005) |
| "Pump thrombus is a potentially serious complication with few available treatment options." | ( Carberry, KE; Chang, AC; Dreyer, WJ; Kennedy, CE; McKenzie, ED; Moffett, BS; Morales, DL; Price, JF; Studer, MA; Teitel, ER, 2006) |
| "Tumour thrombus is a rare complication of many solid cancers including renal cell carcinoma, Wilms' tumour, testicular tumour, adrenal cortical carcinoma, lymphoma, pancreatic cancer, osteosarcoma and Ewing's sarcoma." | ( Bomanji, JB; Ell, PJ; Gacinovic, S; Lai, P; Lee, SM; Mahmood, S; Nagabhushan, N; Syed, R, 2007) |
| "The growing thrombus is visualized in real time from early platelet attachment, through accumulation, to occlusion." | ( Flannery, CJ; Ku, DN, 2007) |
| "Thrombus (blood clot) is implicated in a number of life threatening diseases, e." | ( Caravan, P; Chasse, JM; Deng, Q; Koerner, S; Kolodziej, AF; Looby, RJ; McMurry, TJ; Overoye-Chan, K; Zech, SG, 2008) |
| "Thrombus is present in most if not all patients with a recent history of limb ischemia who are found to have an occluded culprit vessel." | ( Coiner, D; Dippel, EJ; Gayton, L; Jerin, M; Shammas, G; Shammas, NW, 2008) |
| "The risk of LA thrombus is low in patients with a CHADS(2) score of 0 and in patients with an LA diameter < 4." | ( Abraham, TP; Berger, RD; Calkins, H; Cheng, A; Chilukuri, K; Dalal, D; Dong, J; Henrikson, CA; Marine, JE; Nazarian, S; Scherr, D; Spragg, D, 2009) |
| "Because thrombus is inherently avascular, absence of contrast uptake was used as a highly specific identifying feature." | ( Cham, MD; Kim, RJ; Krauser, DG; Min, JK; Tortolani, AJ; Weinsaft, JW; Yang, XJ, 2007) |
| "Aortic thrombus is rare in patients with essential thrombocytosis (ET), so the optimal treatment remains undefined." | ( Blanco Cañibano, E; García Fresnillo, B; Guerra Requena, M; Morata Barrado, PC, 2009) |
| "Venous thrombus is subsequently organized and replaced by fibrous connective tissue." | ( Asada, Y; Asanuma, T; Azuma, T; Furukoji, E; Kawai, K; Kuroiwa, Y; Miyati, T; Sugimura, H; Takahashi, M; Tamura, S; Yamashita, A, 2011) |
| "Contraction of blood clots is necessary for hemostasis and wound healing and to restore flow past obstructive thrombi, but little is known about the structure of contracted clots or the role of erythrocytes in contraction." | ( Cines, DB; Hayes, V; Lebedeva, T; Litvinov, RI; Lowery, TJ; Massefski, W; Nagaswami, C; Rauova, L; Weisel, JW, 2014) |
| "Intracardiac thrombus is a potentially life-threatening condition, with a high risk of embolic complications." | ( Fernández Guerrero, JC; Garcelán Trigo, JA; Lozano Cabezas, C; Padilla Pérez, M; Salas Bravo, D; Torres Llergo, J; Vazquez Ruiz de Castroviejo, E, 2014) |
| "The platelet thrombus is the major pathologic entity in acute coronary syndromes, and antiplatelet agents are a mainstay of therapy." | ( Boutaud, O; Friedman, EA; Haddad, EV; Ogletree, ML, 2015) |
| "Intracoronary thrombus is a common finding in acute coronary syndromes and often correlates with adverse prognosis and complications during percutaneous coronary interventions (PCIs)." | ( Angiolillo, DJ; Bongo, AS; Cavallino, C; Cortese, B; Jaffe, AS; Lupi, A; Porto, I; Rognoni, A; Schaffer, A, 2016) |
| "Thrombus is structured by numerous elements, including endothelial cells, platelets, plasma proteins and shear stress alteration." | ( Shahidi, M, 2017) |
| "A left atrial thrombus is known as a cause of ischaemic stroke." | ( Takeuchi, H, 2017) |
| "The thrombus is detected by utilizing the phenomenon that the phase difference between the impeller displacement and input current to the magnetic bearing increases when a thrombus is formed inside a pump." | ( Arai, H; Fujiwara, T; Hijikata, W; Maruyama, T; Mizuno, T; Murashige, T; Ogata, A; Ouchi, K; Seki, H; Yokota, S, 2020) |
| "Intracardiac thrombus is a rare but serious complication of Behçet's disease." | ( Amchich, Y; Belghoule, R; Boucaid, A; Bourkadi, JE; Reguig, N; Zegmout, A, 2020) |
| "Aortic mural thrombus is a rare complication of CBC but carries a risk of embolic stroke." | ( Ochiai, Y; Tsunogae, M; Ueda, M, 2021) |
| "Blood clots are essential biomaterials that prevent blood loss and provide a temporary scaffold for tissue repair." | ( Bonn, M; Kumar, S; Nisar, A; Parekh, SH; Rausch, MK; Wang, Y, 2021) |
| "Tumour thrombus is an uncommon complication with ominous outcomes." | ( Ahmad, W; Asghar, N; Bashir, H; Zafar, T, 2021) |
| "Ventricular thrombus is an uncommon, severe condition with high morbidity and mortality." | ( Hu, ZX; Huang, H; Lei, S; Liu, X; Wu, Y, 2021) |
| "Since early thrombus is platelet mediated, intravenous platelet glycoprotein inhibitor like eptifibatide is likely to be effective, but rarely utilised in neonates." | ( Mumtaz, ZA; Sivakumar, K, 2022) |
| "Thrombus is one of the major threatening factors to human health and the prevalence of cardio-cerebrovascular diseases induced by thrombus is growing worldwide, even some persons got rare and severe blood clots after receiving the AstraZeneca COVID vaccine unexpectedly." | ( Bai, T; Feng, Q; Guo, T; Jia, J; Li, X; Liu, Y; Pei, J; Song, Y; Wu, L; Wu, S; Zhang, Y; Zheng, X, 2022) |
| "Thrombus are blood clots formed by abnormal hemostasis in blood vessels and are closely associated with various diseases such as pulmonary embolism, myocardial infarction and stroke." | ( Li, M; Li, P; Tang, B; Wang, H; Wang, X; Zhang, W, 2023) |
| "Intracardiac thrombus is a rare presentation of cardiac involvement in BD." | ( Çelikel Acar, B; Çelikel, E; Coşkun, S; Ekici Tekin, Z; Güngörer, V; Gürsu, HA; Güzelküçük, Z; Kaplan, MM; Karagöl, C; Kavurt, AV; Kurt, T; Öner, N; Özbek, NY; Polat, MC; Sezer, M; Tekgöz, PN, 2023) |
| "Thrombus is one of the culprits for global health problems." | ( Fang, YF; Feng, KK; Le, JQ; Luo, BY; Shao, JW; Tan, XR; Tu, YF; Yang, MY; Yin, MD, 2023) |
| Excerpt | Reference |
|---|
| "Moreover, the renal vein thrombus resolved in both cases after eight months on a regimen of oral anticoagulant therapy." | ( Lubowitz, H; Ross, DL, 1978) |
| "Total prevention of mural thrombus in deeply injured arteries is impossible with aspirin or conventional antithrombotic therapy, which can reduce occlusive thrombus." | ( Badimon, JJ; Badimon, L; Chesebro, JH; Roche, PC; Webster, MW; Zoldhelyi, P, 1992) |
| "This reduction in thrombus weight in the animals treated with gold sodium thiomalate was not reflected by changes in platelet survival or fibrinolysis." | ( Buchanan, WW; Hogan, MG; Howard-Lock, HE; Kassam, YB; Kean, WF; Lock, CJ; Nablo, L; Rischke, J; Somers, D, 1991) |
| "With regard to thrombus dimensions, 1 patient treated with ticlopidine showed a decrease in thrombus size associated with a reduction of the scintigraphic activity." | ( Bellotti, P; Chiarella, F; Claudiani, F; Domenicucci, S; Lupi, G; Mazzotta, G; Scopinaro, G; Strada, P; Vecchio, C, 1990) |
| "Similarly, a pronounced inhibition of thrombus formation was observed by in vivo microscopy and computer-assisted morphometric analysis, after oral treatment of non-anesthetized hamsters with dipyridamole, 5 mg/kg." | ( Eisert, WG; Müller, TH, 1990) |
| "We noted intracardiac thrombus in 15 patients; nine of the 15 were started on anticoagulant therapy with warfarin potassium to maintain the prothrombin time between 2." | ( Miyashita, T; Tsuchiya, T; Yamaguchi, T; Yasaka, M, 1990) |
| "Proximal propagation of aortic thrombus with resultant impaired renal perfusion has been considered a significant risk of untreated infrarenal aortic occlusion." | ( Ehrenfeld, WK; Goldstone, J; Reilly, LM; Sauer, L; Stoney, RJ; Weinstein, ES, 1990) |
| "We evaluated the diagnosis of thrombus and the effect of antithrombic therapy by using 67Ga-DFO-DAS-Fibrinogen (67Ga-Fbg." | ( Hachiya, Y; Hirata, K; Iida, M; Kawamura, Y; Matsuzaki, K; Morishita, T; Noguchi, M; Obara, T; Uchi, T; Yamazaki, J, 1990) |
| "Once a thrombus has developed, antithrombotic treatment will prevent its extension, and thrombolytic therapy will try to restore vascular patency." | ( Caen, JP; Drouet, L, 1989) |
| "Therapy that will reduce acute platelet-thrombus deposition appears to be an important factor for reduction of restenosis." | ( Badimon, L; Chesebro, JH; Fuster, V; Lam, JY, 1987) |
| "Calcium content was high in thrombus and increased in all zones with time, in both groups, but the deposition was less in the group treated with hydroxyethylene diphosphonate." | ( Chesebro, JH; Dewanjee, MK; Didisheim, P; Edwards, WD; Kaye, MP; Lenker, J; Mackey, ST; Solis, E; Zollman, PE, 1986) |
| "The amount of thrombus formation appeared to be higher in the PGF2 alpha-treated groups than in controls." | ( Heiss, C; Spanel-Borowski, K, 1986) |
| "Indobufen treatment prevented thrombus formation completely in 14 of 15 rats (p less than 0." | ( Carrieri, P; Cerillo, A; Donzelli, R; Orefice, G; Tayana, G; Volpentesta, G, 1987) |
| "Resolution of the thrombus was documented after 36 hours of treatment with anticoagulant therapy." | ( Baumgartner, G; Davogg, S; Markt, B; Nesser, HJ, 1984) |
| "One week postoperatively, the thrombus-free surface in the treated dogs was 75 percent, compared with 20 percent in control animals; at 2 weeks 97 percent, compared with 38 percent and at 3 weeks 98 percent, compared with 38 percent (p less than 0." | ( Gloviczki, P; Hollier, LH; Kaye, MP; Lovaas, ME, 1983) |
| "Operation to remove thrombus or replace the prosthesis is usually required for left-sided cardiac prostheses, but thrombosed valves in the tricuspid position may be successfully treated with fibrinolytic medical therapy." | ( Brandt, B; Doty, DB; Hiratzka, LF; Wright, JO, 1982) |
| "After a thrombus was allowed to form for 15 minutes in six animals, intravenous treatment with r-hirudin at a dose of 20 nmol (0." | ( Badenhorst, PN; Kotzé, HF; Lamprecht, S, 1995) |
| "Transesophageal echo assessment of thrombus size may be helpful in deciding whether a patient with mitral prosthesis should be treated by anticoagulation, thrombolysis, or valve rereplacement." | ( Bensaid, J; Chabernaud, JM; Fournier, P; Gomez, M; Gueret, P; LaCroix, P; Vignon, P, 1995) |
| "In this study, platelet thrombus formation was induced by irradiation of the mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium." | ( Chao, SH; Huang, TF; Sheu, JR; Yen, MH, 1994) |
| "At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS)." | ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, RJ, 1994) |
| "In untreated controls, thrombus formed rapidly, reaching a plateau by 40 min of 2." | ( Cadroy, Y; Hanson, SR; Harker, LA, 1993) |
| "During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period." | ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993) |
| "or more) also suppressed the thrombus formation by single administration." | ( Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A, 1995) |
| "We report a case of left ventricular thrombus which caused systemic embolism during warfarin therapy." | ( Adachi, K; Araki, S; Ikoma, T; Kawata, M; Mukai, T, 1995) |
| "Monitoring thrombus response with venous duplex imaging should be part of the treatment strategy of deep venous thrombosis if thrombolytic therapy is used." | ( Comerota, AJ; Katz, ML; White, JV, 1996) |
| "This produced an occlusive thrombus in all vehicle-treated ferrets within 41 +/- 3 min with an average weight of 8 +/- 1 mg (n = 7)." | ( Durham, SK; Megill, JR; Schumacher, WA; Steinbacher, TE, 1996) |
| "Platelet-rich thrombus formation was induced by irradiation of the mesenteric venule with filtered light in mice pretreated intravenously with fluorescein sodium." | ( Ko, FN; Kuo, SC; Lee, FY; Teng, CM; Wu, CC, 1997) |
| "Successful thrombus removal utilizing cardiopulmonary bypass and subsequent discharge underscores the importance of surgical therapy in treating this important complication." | ( Burch, KD; Hollingsed, MJ; Morales, JM; Roughneen, PT, 1997) |
| "Others advocate monitoring the thrombus with serial venous duplex scanning and commence treatment if there is evidence of propagation." | ( Fitzgerald, DE; O'Shaughnessy, AM, 1997) |
| "The risk reduction of thrombus formation associated with dalteparin treatment was 0." | ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| "In the subgroup of patients with LA thrombus receiving warfarin therapy, follow-up TEE revealed complete resolution of the thrombi in 6 and partial resolution in the remaining 2 in spite of the persistence of LA spontaneous echo contrast; none of these patients developed clinical thromboembolic events during the study period." | ( Chen, JH; Lin, LJ; Teng, JK; Tsai, LM, 1997) |
| "After ligation of the vena cava the thrombus weight decreased in both CAP and ENA treated rats." | ( Azzadin, A; Buczko, W; Chabielska, E; Golatowski, J; Pawlak, R, 1998) |
| "For treatment of the atrial thrombus, an ultra-low-dose lysis with rt-PA (2 mg/h, intravenously) was administered for a period of 52 h, overlapping with systemic treatment with recombinant hirudin (Lepirudin, Refludan, 0." | ( Eichler, P; Greinacher, A; Kraatz, G; Motz, W; Möx, B; Olbrich, K; Schwock, M; Wacke, W; Wiersbitzky, M; Zinke, H, 1998) |
| "In contrast, platelet thrombus formation was blocked by more than 90% in volunteers treated by aspirin + ticlopidine (P < ." | ( Barret, A; Boneu, B; Bossavy, JP; Cadroy, Y; Sagnard, L; Sakariassen, K; Thalamas, C, 1998) |
| "In five patients thrombus dissolution was achieved using a combination of mechanical and pharmacologic therapy." | ( Greenberg, R; Ivancev, K; Lindblad, B; Lindh, M; Nyman, U; Uher, P; Wellander, E, 1998) |
| "Naked coils embedded in an unorganized thrombus were found in those aneurysms that had been treated with coils within 1 week earlier." | ( Bavinzski, G; Gross, CE; Gruber, A; Killer, M; Plenk, H; Richling, B; Talazoglu, V, 1999) |
| "The change in thrombus mass during thrombolytic therapy is thought to be the difference between its growth and its degradation induced by thrombolytic agents." | ( Giddings, JC; Hashimoto, M; Kawano, M; Sasaki, Y; Taka, T; Watanabe, S; Yamamoto, J; Yamashita, T, 2000) |
| "In the treatment studies, a thrombus was allowed to form for 10 min in six animals." | ( Badenhorst, PN; Kotzé, HF; Lamprecht, S; Roodt, JP; Van Wyk, V, 2000) |
| "With regard to thrombus regression, reviparin administered twice daily was significantly more effective than unfractionated heparin (relative likelihood of thrombus regression, 1." | ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| "The hyperintensity of the thrombus segment depicted on T1-weighted images (thrombus length determined with 3D reconstruction images divided by true thrombus length) increased significantly after administration of contrast medium at a thrombus age of 3 days (0." | ( Coupland, SE; Gust, R; Kresse, M; Schiffler, S; Schmitz, SA; Semmler, W; Wagner, S; Winterhalter, S; Wolf, KJ, 2001) |
| "After warfarin administration, the thrombus disappeared and an echo-free space emerged outside the apical myocardial wall." | ( Endo, M; Ishizuka, N; Iwade, K; Kasanuki, H; Komiya, N; Nakamura, K; Niki, K; Nishikawa, T, 2002) |
| "Maximum thrombus size was larger in the desmopressin and desmopressin + aspirin groups when compared with the group treated with aspirin only." | ( Benkovic, C; Homann, HH; Kuhnen, C; Muehlberger, T; Peter, FW; Steinau, HU; Vogt, PM; Wiebalck, A, 2002) |
| "In addition, a marginal thrombus was now present in the left ventricle despite antithrombotic therapy." | ( Hohmann, C; Jaster, M; Kühl, U; Pauschinger, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U, 2002) |
| "The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention." | ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003) |
| "The diagnosis was thrombus based on the response to treatment." | ( Kitakaze, M; Nakatani, S; Ogata, C; Yamagishi, M; Yasumura, Y, 2003) |
| "Analysis of thrombus dynamics was performed in treated and control mice, using a standardized thrombogenic injury procedure, and the area (size) of the thrombus was measured." | ( Abukhalaf, I; Espinola, RG; Ferrara, DE; Harris, EN; Liu, X; Meroni, PL; Pierangeli, SS, 2003) |
| "The delay in thrombus formation in hemin-treated mice was completely blunted by tin protoporphyrin-IX, a HO-1 inhibitor, but not by copper protoporphyrin-IX, which does not inhibit the enzyme." | ( Bordel, R; Lindenblatt, N; Menger, MD; Schareck, W; Vollmar, B, 2004) |
| "Thus, direct thrombus visualization may be beneficial for both diagnosis and guidance of therapy." | ( Barrett, JA; Botnar, RM; Graham, PB; Hamilton, J; Johnstone, MT; Kolodziej, A; Laredo, J; Manning, WJ; Parsons, EC; Perez, AS; Quist, W; Vaidya, A; Weisskoff, RM; Wiethoff, AJ; Witte, S, 2004) |
| "Once a diagnosis of left ventricular thrombus has been established, the classical attitude consists in the administration of unfractionated heparin relayed by oral anticoagulation therapy." | ( Bourmayan, C; Driss, AB; Grosdemouge, A; Meurin, P; Renaud, N; Tabet, JY; Weber, H, 2005) |
| "After forming an occlusive thrombus in the right carotid artery (RCA), twenty-one dogs were administered recombinant tissue plasminogen activator (rt-PA) intra-arterially to achieve thrombolysis in the presence of either 0." | ( Cardin, AD; Hong, TT; Lucchesi, BR; Van Gorp, CL, 2006) |
| "We present a case of an unusual large thrombus, which resolved with anticoagulation therapy alone, giving hope that more invasive intervention can safely be circumvented." | ( Al-Khuwaitir, TS; Alafifi, E; Wani, BA; Zaidi, SM, 2005) |
| "In an in vivo study, thrombus formation was induced by irradiation of mesenteric venules in mice pretreated with fluorescein sodium." | ( Chou, DS; Fong, TH; Hsiao, G; Lin, KH; Shen, MY; Sheu, JR; Tzu, NH; Wang, Y, 2005) |
| "Treatment with rhsTM reduced thrombus propagation rates, prolonged the clotting and bleeding times, decreased thrombin-antithrombin complex, beta-thromboglobulin and fibrinopeptide A levels, and, surprisingly, also decreased systemic APC levels, in a dose-dependent manner." | ( Fernández, JA; Griffin, JH; Gruber, A; Hanson, SR; Kelly, AB; Marzec, UM; Mohri, M; Tanaka, KA, 2006) |
| "There was a significant decrease in thrombus weight with the crude extract and all fractions tested after 10 days treatment with 2." | ( Al Awwadi, NA; Borrot-Bouttefroy, A; Canal, M; Garreau, C; Glories, Y; Moore, N; Saucier, C; Segur, MC; Umar, A, 2007) |
| "Pump thrombus is a potentially serious complication with few available treatment options." | ( Carberry, KE; Chang, AC; Dreyer, WJ; Kennedy, CE; McKenzie, ED; Moffett, BS; Morales, DL; Price, JF; Studer, MA; Teitel, ER, 2006) |
| "In vivo, the thrombus size increased significantly when treated with IS6 compared with control-treated mice (5388 +/- 1035 microm2 vs." | ( Chen, P; Kwan-Ki, H; Liu, X; Pierangeli, S; Vega-Ostertag, M, 2006) |
| "In a rat model of a platelet-rich thrombus induced by vessel injury with FeCl(2), both BX 667 and clopidogrel exhibited higher levels of thrombus inhibition after oral administration compared to their potency in the A-V shunt model." | ( Alexander, S; Bryant, J; Buckman, BO; da Cunha, V; Dole, WP; Fitch, RM; Islam, I; Mallari, C; Martin-McNulty, B; Morser, J; Post, JM; Subramanyam, B; Sullivan, ME; Vergona, R; Vincelette, J; Wang, YX; Yuan, S, 2007) |
| "The tricuspid valve thrombus disappeared after anticoagulant therapy." | ( Basarici, I; Belgi, A; Yalcinkaya, S, 2008) |
| "Furthermore, thrombus weight and the cell/fibrinogen counts were significantly increased in fonda and fonda+eptifibatide compared with other treatment groups." | ( Buerke, M; Carter, JM; Ebelt, H; Hauroeder, B; Kropff, SS; Maegdefessel, L; Peetz, D; Reindl, I; Rupprecht, HJ; Russ, M; Schlitt, A; Schmidt, H; Schubert, S; Werdan, K, 2008) |
| "Nicorandil attenuates FeCl(3)-induced thrombus formation in the mouse testicular artery, which suggests that it may inhibit the generation of reactive oxygen species by FeCl(3)-treated endothelial cells through activation of the mitochondrial ATP-sensitive potassium channels." | ( Eguchi, Y; Higashijima, N; Ishida, H; Ishizuka, N; Kawamura, Y; Takahari, Y; Tamura, N, 2009) |
| "Aortic thrombus is rare in patients with essential thrombocytosis (ET), so the optimal treatment remains undefined." | ( Blanco Cañibano, E; García Fresnillo, B; Guerra Requena, M; Morata Barrado, PC, 2009) |
| "There was no evidence of thrombus formation during venous stasis in any Haemocomplettan P-treated animal." | ( Bergman, GE; Dickneite, G; Joch, C; Pragst, I, 2009) |
| "The incidence of thrombus in patients treated with sodium ozagrel was lower than patients treated without sodium ozagrel (P < 0." | ( Chen, WT; Ding, YP; Fu, XJ; Huang, L; Lin, LE; Wang, H; Wu, CM; Yao, HX, 2010) |
| "We present a rare case of a thrombus at the aortic arch found 1 month after cisplatin-based chemotherapy in a 50-year-old patient with a diagnosis of small cell lung cancer; there were no symptoms related to the thrombus." | ( Baek, SK; Chin, SO; Choi, CW; Han, JJ; Hwang, YH; Lee, JJ; Maeng, CH, 2010) |
| "No reductions were observed in the thrombus size or mean mitral gradient on transesophageal echocardiography (TEE) with 1 week of unfractioned heparin therapy." | ( Akcay, AB; Akcay, M; Davutoglu, V; Sen, N; Soydinc, HE; Yuce, M, 2011) |
| "On untreated Ti surfaces blood clots remain thin (below 15 mm), patchy and non-structured lacking large fibrin fiber networks whereas blood clots on differentiated surfaces assemble in an organized and layered architecture of more than 30 mm thickness." | ( Hall, H; Milleret, V; Schlottig, F; Tugulu, S, 2011) |
| "Effects of AZD0837 and ximelagatran on thrombus formation were similar or greater than for VKA therapy and correlated with plasma concentrations of their active forms." | ( Elg, M; Eriksson, UG; Gouya, G; Holmberg, M; Kapiotis, S; Leuchten, N; Schützer, KM; Wåhlander, K; Wolzt, M; Zetterstrand, S, 2012) |
| "Left atrial (LA) thrombus was sometimes found by transesophageal echocardiography (TEE) in non-valvular atrial fibrillation (AF), even in the setting of continuous warfarin therapy." | ( Fujii, E; Ito, M; Nakamura, M; Senga, M; Sugiura, E; Sugiura, S, 2012) |
| "These results suggested pENW attenuated thrombus formation in part by inhibiting platelet activation instead of coagulation factors, presented evidence of pENW interfering intracellular signaling system in the process of platelet activation and indicated the possibility that pENW could potentially be developed as a novel therapeutic agent in the prevention and treatment of thrombotic disorders." | ( Bai, L; Cen, J; Fang, W; Fu, J; Kong, Y; Li, Y; Xiong, J, 2012) |
| "In-stent thrombus formation was analyzed under different treatments: vehicle (n = 7 animals); intravenous (i." | ( Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E, 2012) |
| "Compared with model group, the thrombus area on aorta in pravastatin-treated group was reduced." | ( Huang, C; Huang, Z; Jiang, H; Wu, G; Xie, Q; Xu, L, 2013) |
| "Targeting platelet-mediated thrombus formation with dual antiplatelet therapy comprising acetylsalicylic acid and a P2Y12 antagonist is the current mainstay for management of ACS." | ( White, H, 2014) |
| "Ex vivo thrombus formation was assessed in the Badimon chamber at low and high shear rates in 2 double-blind randomized cross-over studies of 20 healthy volunteers during extracorporeal administration of recombinant t-PA (0, 40, 200, and 1000 ng/mL) or during endogenous t-PA release stimulated by intra-arterial bradykinin infusion in the presence or absence of oral enalapril." | ( Boon, NA; Faratian, D; Fox, KA; Gibson, KR; Lucking, AJ; Ludlam, CA; Newby, DE; Paterson, EE, 2013) |
| "Both leukocyte adherence and thrombus formation were inhibited by treatment with fondaparinux." | ( Aihara, K; Iba, T; Koichiro, N; Ohsaka, A; Watanabe, S; Yamada, A; Yanagawa, Y, 2013) |
| "In the extract treatment groups, the thrombus was filament-like and did not adhere to blood vessel walls, whereas in the control group the thrombus was thick and almost completely occluded the vein." | ( Dub, AM; Dugani, AM, 2013) |
| "In vitro: after the administration of thrombus-targeted BLs or non-targeted BLs, the clot was exposed to low-frequency (27 kHz) USD for 5 min." | ( Hagisawa, K; Iida, K; Ishihara, M; Kurita, A; Luo, H; Maruyama, K; Nishida, Y; Nishioka, T; Siegel, RJ; Suzuki, R; Takase, B; Yoshimoto, N, 2013) |
| "In vivo microthrombus formation in laser-injured vessels significantly increased in fibrinogen-treated animals compared with sham (77% vs 18%)." | ( Cabrales, P; Fries, D; Intaglietta, M; Martini, J; Tsai, AG, 2013) |
| "Resolution of the thrombus and eventual resumption of normal prosthetic mitral valve function was obtained through treatment with low-molecular weight heparin (LMWH)." | ( Elkayam, U; Goland, S; Levy, R; Perlman, S; Schwartzenberg, S, 2013) |
| "Arterial thrombus formation was delayed in mice treated with PIK75 when compared with controls." | ( Akhmedov, A; Beer, JH; Camici, GG; Eickner, T; Holy, EW; Jakob, P; Lüscher, TF; Schmitz, KP; Sternberg, K; Tanner, FC, 2014) |
| "Dissolution of the thrombus local catheter-directed intra-arterial infusion of fibrinolytic agents such as urokinase is the standard therapy for thrombosis; however, this method is time-intensive, and amputation of the affected limb is still needed in 10-30% of cases." | ( Meyer, KW; Musters, RJ; Nederhoed, JH; Slikkerveer, J; Wisselink, W; Yeung, KK, 2014) |
| "Our demonstration that flavonols delay thrombus formation in diabetes suggests a potential clinical role for these compounds in anti-platelet therapy." | ( Jackson, DE; Linden, MD; Mosawy, S; Woodman, OL, 2014) |
| "ZDF rats displayed accelerated thrombus formation and were amenable to apixaban treatment in the A-V shunt model albeit with less sensitivity than normal rats." | ( Chen, Z; Chintala, M; Feng, W; Graziano, MP; Li, Q; Shang, J; Wang, M; Wu, W; Wu, Y, 2014) |
| "The platelet thrombus is the major pathologic entity in acute coronary syndromes, and antiplatelet agents are a mainstay of therapy." | ( Boutaud, O; Friedman, EA; Haddad, EV; Ogletree, ML, 2015) |
| "Tail-thrombus of the enzyme treated group was significantly shorter than the physiological saline treated group and the thrombus decrement was correlated with the enzyme dose." | ( Cheng, H; Fu, T; Guo, L; Li, B; Tian, Z; Wu, M; Zhu, H, 2015) |
| "Platelet activation is essential for thrombus formation and is thus an important target for pharmacological intervention to prevent and treat AMI." | ( Farag, M; Gorog, DA; Patel, H, 2015) |
| "The assessment of thrombus size following treatments directed at preventing thrombosis or enhancing its resolution has generally relied on physical or histological methods." | ( Grover, SP; Jenkins, J; Lyons, OT; Modarai, B; Mukkavilli, A; Patel, AS; Saha, P; Smith, A; Sunassee, K, 2015) |
| "Furthermore, PPD exacerbated thrombus formation in rats in comparison with those untreated." | ( Bagri, A; Boufous, H; Chait, A; Darif, Y; Habti, N; Kojok, K; Marhoume, F; Mohamed, F; Naya, A; Oudghiri, M; Senhaji, N; Zaid, Y; Zouine, S, 2016) |
| "The authors underline that thrombus formation may develop in atrial fibrillation even if the patient is adequately treated with rivaroxaban." | ( Gellér, L; Merkely, B; Szegedi, N; Széplaki, G; Tahin, T, 2016) |
| "The presence of older thrombus provides independent complementary information to a multimarker model including established clinical risk factors and multiple biomarkers for predicting 1-year mortality in STEMI patients treated with pPCI and thrombus aspiration." | ( Baan, J; Damman, P; de Winter, RJ; Fischer, JC; Grundeken, MJ; Henriques, JP; Koch, KT; Kramer, MC; Li, X; Piek, JJ; Tijssen, JG; van der Wal, AC; van Straalen, JP; Vis, MM, 2016) |
| "However, it is not clear how thrombus develops following flow-diversion treatment." | ( Huang, W; Ou, C; Yuen, MM, 2017) |
| "Patients/Methods Platelet thrombus formation in the whole blood of 94 patients with ischemic cerebrovascular disease treated with clopidogrel and/or aspirin was measured in a flow chamber system at a shear rate of 1500 s(-1) and was compared with the results of assays for agonist-induced platelet aggregability, phosphorylation of vasodilator-stimulated phosphoprotein, platelet p-selectin expression (PS), and platelet-monocyte complexes." | ( Hosokawa, K; Kawashima, A; Kitagawa, K; Ohnishi, T; Okada, Y; Uchiyama, S; Yamaguchi, K; Yamazaki, M; Yoneyama, T, 2016) |
| "Platelet activation and thrombus formation were also suppressed when directly treated with 12(S)-HETrE." | ( Adili, R; Fernandez-Perez, P; Freedman, CJ; Green, AR; Holinstat, M; Holman, TR; Tourdot, BE; Yeung, J; Yu, J, 2016) |
| "CLOT-AF retrospectively collected thrombus-related patient outcome data after standard-of-care anticoagulant treatment for 3 to 12 weeks in patients with nonvalvular AF or atrial flutter who had LA/LAA thrombi on TEE recorded in their medical file." | ( Cappato, R; Cohen, A; Hammerstingl, C; Kirsch, B; Lip, GY; Marin, F; Meng, IL; van Eickels, M, 2016) |
| "TEE demonstrated thrombus in the LAA on day 4, and edoxaban therapy (60 mg once daily) was initiated." | ( Saito, S; Shindo, S; Shirakawa, M; Tsudaka, S; Uchida, K; Yoshimura, S, 2016) |
| "Left atrial appendage thrombus had been detected even under anticoagulation therapy." | ( Fujisaki, M; Inoue, T; Morizumi, S; Ohtsuka, T; Suematsu, Y; Yoshimoto, A, 2016) |
| "The incidence of LAA thrombus was higher in patients treated with warfarin (1." | ( Atwater, BD; Bahnson, TD; Campbell, KB; Daubert, JP; Samad, Z; Steinberg, BA; Velazquez, EJ; Wyrembak, J, 2017) |
| "5 U of PC increased thrombus size in clopidogrel-treated patients (P < ." | ( Calmer, S; Echtermeyer, F; Jahn, K; Johanning, K; Küster, U; Sahlmann, B; Schäfer, A; Suchodolski, K; Theilmeier, G, 2017) |
| ": A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy." | ( Baldi, M; Ciconte, G; Conti, M; Pappone, C; Saviano, M; Vicedomini, G, 2017) |
| "After two weeks on that therapy, the thrombus in the LAA was successfully resolved." | ( Idei, N; Kaseda, S; Ohashi, N; Okada, T; Takaekou, Y, 2017) |
| "This study aimed to evaluate thrombus composition and its association with clinical, laboratory, and neurointerventional findings in patients treated by mechanical thrombectomy due to acute large vessel occlusion." | ( Kitano, Y; Kobayashi, K; Maekawa, K; Miya, F; Mizutani, A; Mori, G; Naito, Y; Nakajima, H; Sano, T; Seguchi, M; Shibata, M; Shimizu, S; Yabana, T; Yamasaki, M, 2018) |
| "KPI and KPIHSA similarly reduced thrombus size and occlusion in both venous and arterial thrombosis models when administered at the time of injury, but only KPI was effective when administered one hour before injury." | ( Bhakta, V; Eltringham-Smith, LJ; Sheffield, WP, 2018) |
| "Platelet function and thrombus formation are impaired in MRP4 knockout mice models, and, among aspirin-treated patients, high on-aspirin residual platelet reactivity (HARPR) positively correlates with MRP4 levels." | ( Alemanno, L; Angiolillo, DJ; Frati, L; Guarino, ML; Klaus, V; Maltese, T; Massimi, I; Pulcinelli, FM, 2018) |
| "Left atrial thrombus (LAT) and dense spontaneous echocardiographic contrast (SEC) detected by transesophageal echocardiography (TEE) in patients on continuous direct oral anticoagulants (DOAC) therapy before catheter ablation of atrial fibrillation (AF) or atrial flutter (AFL) have been described." | ( Cheung, JW; D'Amato, S; Gabriels, J; Ip, JE; Khan, M; Lerman, B; Liu, CF; Markowitz, SM; Patel, A; Shaban, N; Singh, P; Thomas, G; Wu, M, 2018) |
| "EPS also showed remarkable reduction in thrombus formation when administered in occlusion induced thrombotic rats at a low dose (2." | ( Abid, M; Ahmad, I; Ashraf, MZ; Gupta, N; Jairajpuri, MA; Rashid, Q; Sharma, S, 2018) |
| "Left atrial thrombus (LAT) may be detected by transesophageal echocardiography (TEE) in patients with atrial fibrillation (AF) or flutter (AFL) despite continuous anticoagulation therapy." | ( Cheung, JW; D'Amato, SA; Gabriels, J; Ip, JE; Khan, M; Lerman, BB; Liu, CF; Markowitz, SM; Patel, A; Shaban, N; Singh, P; Thomas, G; Wu, MS, 2018) |
| "The timely detection of the thrombus facilitated early initiation of anticoagulant therapy." | ( Bahl, A; Gulati, A; Kumar, R; Mittal, BR; Parihar, AS; Prakash, G; Singh, S; Singhal, M; Sood, A, 2018) |
| "Unlike an untreated PEEK valve, no thrombus formed on the PEEK-g-PMPC valves on gross anatomy examination in addition to the absence of traveled thrombi in the kidney and lung tissues." | ( Fukazawa, K; Ishihara, K; Kakinoki, S; Kambe, Y; Kyomoto, M; Liu, Y; Mahara, A; Minatoya, K; Tanaka, H; Yamaoka, T, 2019) |
| "Data on LA/LAA thrombus resolution after rivaroxaban treatment has not been established." | ( He, Y; Ke, HH; Li, JY; Lv, XW; Wei, Z; Zhang, EH, 2019) |
| "An HCC patient developed a thrombus in the SMA during TKI therapy." | ( Abe, Y; Fujita, M; Fukutake, N; Hasegawa, N; Ikezawa, K; Imai, T; Katayama, K; Kiyota, R; Nawa, T; Ohkawa, K; Sakakibara, M; Takada, R, 2020) |
| "After 10 min of sonothrombolysis treatment of the blood clot in blood, the US and PA SNR values increased by 7." | ( Das, D; Pramanik, M, 2019) |
| "A large thrombus was first detected following mitral valve surgery despite effective vitamin K antagonist anticoagulation therapy." | ( Masarova, L; Novak, J; Ondrasek, J; Panovsky, R; Pesl, M; Semenka, J; Simarova, E, 2020) |
| "Development of a thrombus after mitral valve surgery despite effective anticoagulant therapy and its final resolution by introducing a combination of rivaroxaban and clopidogrel highlights the complex etiopathogenesis of thrombus formation." | ( Masarova, L; Novak, J; Ondrasek, J; Panovsky, R; Pesl, M; Semenka, J; Simarova, E, 2020) |
| "After sixth months, when no thrombus was identified at transthoracic echocardiographic examinations, the treatment was stopped." | ( Casucci, F; Covella, B; Libutti, P; Lomonte, C; Rossi, L; Teutonico, A, 2021) |
| "The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy." | ( Dahlen, J; Hosokawa, K; Nagasato, T; Ohnishi-Wada, T; Oyamada, C; Sameshima-Kaneko, H, 2020) |
| "These data suggest improved thrombus resolution in post-acute coronary syndrome (ACS) LV thrombosis in patients treated with NOACs compared to VKAs." | ( Alizadeh, MA; Antoniou, S; Baumbach, A; Fhadil, S; Guttmann, O; Jones, DA; Knight, C; Mathur, A; Rathod, KS; Timmis, A; Wragg, A; Wright, P, 2021) |
| "After thrombus aspiration and intracoronary administration of 0." | ( Chen, Y; Wang, B; Wang, W; Wei, S, 2021) |
| "In addition, the rates of thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death between NOAC- and warfarin-treated patients were also similar." | ( Chen, H; Deng, Y; He, T; Hu, J; Jiang, X; Li, S; Liu, L; Tong, Y; Xiong, Q, 2021) |
| "We compare thrombus changes in a series of images according to time and describe the approach to treatment and thrombosis resolution." | ( Kim, KY; Lee, SH, 2021) |
| "warfarin in treating LV thrombus after MI." | ( Alcalai, R; Amir, O; Butnaru, A; Elbaz-Greener, G; Ibrahimli, M; Leibowitz, D; Moravsky, G; Planer, D; Rashad, R; Yagel, O, 2022) |
| "Meanwhile, the thrombus can cut off the blood oxygen supply and potentiate the hypoxia levels to enhance the HAP therapy." | ( Dai, X; Foda, MF; Han, H; Ma, Z; Zhang, J; Zhang, W; Zhang, Y; Zhao, Y, 2021) |
| "In LPS-treated mice, the PECAM-1/thrombus ratio decreased as the dose of ASA increased in both thrombosis models, but the direction of change in the thrombus area was inconsistent." | ( Chabielska, E; Gromotowicz-Poplawska, A; Marcinczyk, N; Misztal, T; Radziwon, P; Rusak, T; Zebrowska, A, 2021) |
| "Regression of thrombus in response to treatment with direct oral anticoagulants (DOACs) in patients with extensive deep vein thrombosis (DVT) has not been fully evaluated." | ( Araki, H; Fujioka, S; Fukuzumi, M; Goto, H; Kitamura, T; Mishima, T; Miyaji, K; Onishi, Y; Sasahara, A; Shikata, F; Torii, S, 2022) |
| "Quantitative thrombus CT characteristics on thin-slice admission CT improve prediction of thrombus composition and might be used to further guide clinical decision-making in patients treated with EVT for AIS in the future." | ( Arrarte Terreros, N; Bokkers, RPH; Boodt, N; Dippel, DWJ; Hund, H; Lingsma, HF; Lycklama À Nijeholt, GJ; Majoie, CBLM; Marquering, HA; Taha, A; van Beusekom, HMM; van der Lugt, A; van Es, ACGM, 2022) |
| "Multiparameter assessment of thrombus formation showed suppressed platelet aggregate and fibrin formation upon eptifibatide treatment, in contrast to the other variants." | ( Brouns, SLN; Dijkgraaf, I; Hackeng, TM; Nagy, M; Suylen, DPL; van den Kerkhof, DL; Wichapong, K, 2022) |
| "The effect and safety of thrombus provide a new strategy for realizing combined treatment of thrombus." | ( Guo, Y; Han, S; Li, Y; Zhang, H; Zhang, L, 2022) |
| "The composition of an acute ischemic thrombus may reflect the pathophysiology of stroke and influence treatment efficacy." | ( Deguchi, J; Hatakeyama, K; Kubo, M; Matsumoto, M; Myochin, K; Nakagawa, I; Obayashi, C; Saito, K; Sakai, K; Shimada, K; Shimizu, H; Shobatake, R; Sugie, K; Takahashi, N; Tokunaga, H; Yamashita, A, 2022) |
| "Patients with STEMI and a high thrombus burden who underwent thrombus aspiration and primary PCI were randomly allocated to pro-UK administration or control groups." | ( Cao, M; Gao, J; Meng, X; Wang, Z; Xu, Z; Yu, S; Zhang, H; Zhu, W, 2022) |
| "Patients with STEMI and a high thrombus burden who underwent thrombus aspiration and primary PCI were randomly allocated to pro-UK administration or control groups." | ( Cao, M; Gao, J; Meng, X; Wang, Z; Xu, Z; Yu, S; Zhang, H; Zhu, W, 2022) |
| "Early diagnosis and treatment of thrombus is the key to reducing the high risk of thrombotic disease." | ( Li, M; Li, P; Tang, B; Wang, H; Wang, X; Zhang, W, 2023) |
| "There was complete resolution of the thrombus with this treatment and the patient had no significant bleeding while receiving treatment." | ( Curzon, C; Murray, G; Raulji, C; Soffer, OD; Taylor, R, 2023) |
| "Patients with a history of LV thrombus < 3 months and with systemic anticoagulation therapy < 1 month were included." | ( Feng, G; Liang, Y; Quan, X; Wang, C; Yang, Q; Yang, Y; Yu, D; Yu, L; Zhang, T; Zhang, Y; Zhu, J, 2023) |
| "We observed that the thrombus formation rate and the size of the thrombus were greatly reduced in 11,12-EET treated mice，accompanied by decreased TF and inflammatory cytokines expression." | ( Dong, R; Fu, M; Li, W; Luo, J; Luo, L; Tu, L; Yang, Y, 2023) |
| "Integrating a thrombus-homing strategy with photothermal therapy are proposed to address these limitations." | ( Chen, YT; Chiang, CC; Chuang, EY; Fan, YJ; Lin, CW; Liu, KT; Liu, MH; Quiñones, ED; Wu, KC; Yu, J, 2023) |
| "In Patients with STEMI, intracoronary thrombus architecture was significantly altered between patients pre-treated with prasugrel when compared to clopidogrel." | ( Baas, L; Gawaz, MP; Geisler, T; Gekeler, S; Harm, T; Kreisselmeier, KP; Müller, II; Müller, KAL; Prang, C; Rath, D; Schröder, S, 2023) |